This study identifies how overweight status reprograms the pancreatic tumor microenvironment through cell-type-specific changes using Bayesian modeling and interactome analysis.

bioRxiv · Jun 3, 2026 · PreprintCancer Biology

Uttroside B, a US FDA-designated Orphan drug, mitigates thedevelopment of hepatocellular carcinoma and its pulmonary metastasis via EGFR/ERK-mediated inhibition of SREBP-1 and STAT-3

Chenicheri Kizhakkeveettil Keerthana, Tennyson Prakash Rayginia, Kalimuthu Kalishwaralal, Sandhini Saha, Nair Hariprasad Haritha, Amrutha Nisthul A., Mundanattu Swetha, Sreekumar Usha Devi Aiswarya, Lekshmi R. Nath, Sanjay Suresh Varma, Arun (Geetha) Viswanathan, Somaraj Jannet, Shirly J, Jayasekharan S. Aparna, Archana Praveen, , Ruby John Anto

This study shows that Uttroside B inhibits hepatocellular carcinoma and its pulmonary metastasis by blocking the EGFR/ERK pathway and its downstream targets SREBP-1 and STAT-3.

Cell Death Discovery · Apr 16, 2026Peer-reviewedCancer Biology

Evaluating the therapeutic efficacy of the US FDA-designated Orphan drug, uttroside B in impeding hepatocarcinogenesis via induction of immunogenic apoptosis, using a murine model of Aflatoxin B1-induced liver carcinogenesis

Mundanattu Swetha, Chenicheri Kizhakkeveettil Keerthana, Tennyson Prakash Rayginia, Kalimuthu Kalishwaralal, Sadiq Chembothumparambil Shifana, Sreekumar Usha Devi Aiswarya, Lekshmi R. Nath, Sanjay Suresh Varma, Arun (Geetha) Viswanathan, Somaraj Jannet, J Shirly, Jayasekharan S. Aparna, Sankar Sundaram, Nikhil Ponnoor Anto, Noah Isakov, , Ruby John Anto

This study evaluates uttroside B's efficacy in preventing AFB1-induced hepatocarcinogenesis in mice by inducing immunogenic apoptosis and blocking immune checkpoints.

bioRxiv · Sep 8, 2025 · PreprintCancer Biology